

■ eAppendix Table 1. Input Data

Variable	Baseline Estimate	Lowest Estimate	Highest Estimate	Threshold Value	Strategy Favored by Values Higher (Lower) Than Threshold
<b>Quarterly cost, \$</b>					
SFC	679	608	815	736	Salmeterol
Salmeterol	326	297	389	303	(Salmeterol)
Fluticasone	428	419	436	NA	—
<b>Cost, \$</b>					
COPD hospitalization	5158	4160	6252	NA	—
Minor exacerbation	132	106	159	NA	—
<b>Relative utility weight</b>					
During minor exacerbation	0.85	0.70	0.93	NA	—
During COPD hospitalization	0.70	0.40	0.85	NA	—
<b>Quarterly rate of death, %</b>					
Placebo	1.37	0.90	1.45	NA	—
SFC	1.12	0.91	1.37	1.24	Salmeterol
Salmeterol	1.20	0.97	1.46	1.14	(Salmeterol)
Fluticasone	1.44	1.20	1.77	1.28	(Fluticasone)
<b>Quarterly rate of COPD hospitalization, %</b>					
Placebo	4.75	4.13	5.73	NA	—
SFC	4.00	3.38	4.66	NA	—
Salmeterol	4.00	3.28	4.56	3.69	(Salmeterol)
Fluticasone	4.25	3.52	4.89	NA	—
<b>Quarterly rate of minor exacerbation, %</b>					
Placebo	0.20	0.18	0.23	NA	—
SFC	0.12	0.10	0.13	NA	—
Salmeterol	0.16	0.14	0.18	NA	—
Fluticasone	0.13	0.12	0.15	NA	—
<b>Utility weight of COPD</b>					
Placebo	0.569	0.558	0.580	NA	—
SFC	0.603	0.592	0.614	0.599	(Salmeterol)
Salmeterol	0.580	0.569	0.591	0.582	Salmeterol
Fluticasone	0.591	0.580	0.601	0.596	Fluticasone
<b>Discount rate for future costs and effects, %</b>					
	3	0	7	NA	—

COPD indicates chronic obstructive pulmonary disease; NA, not applicable; SFC, salmeterol–fluticasone propionate combination.


## Cost-Effectiveness of Salmeterol, Fluticasone, and Combination Therapy for COPD

**■ eAppendix Table 2.** Discounted Absolute and Incremental Costs and Effectiveness and Incremental Cost-Effectiveness Ratios in the Alternative Analysis Using Pooled Data<sup>a</sup>

Strategy	Total Cost, \$	Total Effectiveness, QALYs Gained	Incremental Cost, \$ <sup>b</sup>	Incremental Effectiveness, QALYs Gained <sup>b</sup>	Incremental Cost-Effectiveness Ratio, \$/QALY Gained <sup>b</sup>
Placebo	2780	1.444	—	—	—
Salmeterol	6104	1.505	3324	0.061	54,492
Fluticasone propionate	7011	1.495	907	-0.01	Dominated <sup>c</sup>
SFC	9650	1.566	3546	0.061	58,131

QALY indicates quality-adjusted life-year; SFC, salmeterol-fluticasone propionate combination.  
<sup>a</sup>All costs are in 2006 US dollars.  
<sup>b</sup>Relative to the next less costly or less effective strategy. Values are rounded.  
<sup>c</sup>Dominated by salmeterol.

**■ eAppendix Figure.** Scatterplot of Incremental Costs and Quality-Adjusted Life-Years (QALYs)



SFC indicates salmeterol-fluticasone propionate combination.